![Melanoma Antibody [PNL2] 抗体，orb1252406，Biorbyt产品图](https://img1.dxycdn.com/p/s14/2026/0729/505/4876880692122632802.jpg)
- ￥13338
- Biorbyt
- orb1252406
- 英国
- 2026年07月31日
- IF, IHC-P, WB
- Mouse
- Canine, Human, Mouse
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
从原料到标记，打造属于中国自己的流式抗体品牌Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Melanoma Antibody [PNL2] 抗体
- 抗体英文名：
Melanoma Antibody [PNL2]
- 浓度：
0.2 mg/mL
- 应用范围：
IF, IHC-P, WB
- 宿主：
Mouse
- 适应物种：
Canine, Human, Mouse
- 保质期：
12 months from date of receipt.
- 抗原来源：
详询
- 目录编号：
orb1252406
- 级别：
科研
- 库存：
99
- 供应商：
Biorbyt
- 标记物：
Unconjugated
- 克隆性：
Monoclonal
- 保存条件：
详询
- 形态：
Liquid
- 亚型：
IgG1
- 免疫原：
详询
- 规格：
100 ug
产品子类型: Primary Antibody
描述: Melanoma Antibody [PNL2]
克隆号: PNL2
应用说明: Immunofluorescence: 0.5-1 µg/mLImmunohistochemistry (FFPE): 0.5-1 µg/mL for 30 min at RT (1)Prediluted format: incubate for 30 min at RT (2)Optimal dilution of the Melanoma antibody PNL2 should be determined by the researcher.1. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 min.2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
免疫原: Melanocyte antigen was used as the immunogen for the Melanoma antibody PNL2.
防腐剂: PBS with 0.1 mg/ml rAlbumin and 0.05% sodium azide
纯化方法: Protein G affinity chromatography
研究领域: Cancer Biology
保存条件: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
备注: For research use only.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Detection of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Melanoma
The tumor antigen chondroitin sulfate proteoglycan 4 (CSPG4) appears to be a useful biomarker to identify melanoma cells and an attractive target to apply antibody-based immunotherapy for the treatment of melanoma. Here we described
Isolation of Melanoma Cell Subpopulations Using Negative Selection
are highly important to develop novel targeted therapies. However, this can be a challenging task as there is a lack of clearly defined markers to distinguish the melanoma subpopulations from a general tumor cell population. Also, there is a lack of optimal
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
